Patterns of symptom reporting during pregnancy comparing opioid maintained and control women

Andrea L. Gordon, Olga V. Lopatko, Helen Stacey, Vicki Pearson, Anna Woods, Ann Fisk, Jason M. White

Research output: Contribution to journalArticle

Abstract

Objective: To characterize the range of symptoms experienced by pregnant methadone-maintained (MM) and buprenorphinemaintained (BM) women to determine whether these differ from those experienced by a control group of nonopioid exposed pregnant women. Opioid-maintained (OM) patients report high rates of symptoms related to direct opioid effects and withdrawal. Pregnancy is associated with a range of symptoms, some overlapping with opioid effects and withdrawal. Methods: Prospective, nonrandomized, open-label comparison study undertaken in a large teaching maternity hospital in South Australia. Pregnant BM(n=25),MM(n=25) and nonopioid exposed controls (n=25) were recruited and matched for age, parity, gravidity, alcohol consumption, and smoking status. Symptom report patterns, maternal withdrawal, and additional substance use were assessed. Results: MM women reported 10 and BM women reported 2 symptoms throughout pregnancy at rates greater than controls.Methadonemaintained women reported significantly (P < 0.05) more symptoms than BM women compared to controls throughout pregnancy. Methadone-maintained women reported 8 and BM women reported 3 symptoms in the third trimester at rates greater than controls. Methadone-maintained women reported greater opioid withdrawal than controls; this did not occur in BM women. Additional substance use was comparable between BM and MM women but greater than controls. Conclusions: Patterns of symptom reports may have clinical implications for maternal and fetal health during pregnancy for OM women including optimization of opioid dosing regimens, education regardingmaternal nutritional intake and preventing postnatal depression, thereby ensuring maternal health and fetal development during pregnancy and enhancing mother-infant bonding and healthy child development postnatally.

Original languageEnglish (US)
Pages (from-to)258-264
Number of pages7
JournalJournal of Addiction Medicine
Volume6
Issue number4
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Opioid Analgesics
Pregnancy
Methadone
Mothers
Gravidity
Postpartum Depression
Maternity Hospitals
South Australia
Third Pregnancy Trimester
Pregnancy Rate
Fetal Development
Child Development
Parity
Teaching Hospitals
Alcohol Drinking
Pregnant Women
Smoking
Education
Control Groups

Keywords

  • Buprenorphine
  • Methadone
  • Opioid maintained
  • Pregnancy
  • Symptom

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Gordon, A. L., Lopatko, O. V., Stacey, H., Pearson, V., Woods, A., Fisk, A., & White, J. M. (2012). Patterns of symptom reporting during pregnancy comparing opioid maintained and control women. Journal of Addiction Medicine, 6(4), 258-264. https://doi.org/10.1097/ADM.0b013e31826b299d

Patterns of symptom reporting during pregnancy comparing opioid maintained and control women. / Gordon, Andrea L.; Lopatko, Olga V.; Stacey, Helen; Pearson, Vicki; Woods, Anna; Fisk, Ann; White, Jason M.

In: Journal of Addiction Medicine, Vol. 6, No. 4, 12.2012, p. 258-264.

Research output: Contribution to journalArticle

Gordon, AL, Lopatko, OV, Stacey, H, Pearson, V, Woods, A, Fisk, A & White, JM 2012, 'Patterns of symptom reporting during pregnancy comparing opioid maintained and control women', Journal of Addiction Medicine, vol. 6, no. 4, pp. 258-264. https://doi.org/10.1097/ADM.0b013e31826b299d
Gordon, Andrea L. ; Lopatko, Olga V. ; Stacey, Helen ; Pearson, Vicki ; Woods, Anna ; Fisk, Ann ; White, Jason M. / Patterns of symptom reporting during pregnancy comparing opioid maintained and control women. In: Journal of Addiction Medicine. 2012 ; Vol. 6, No. 4. pp. 258-264.
@article{447d645089bb439da4e962abad839863,
title = "Patterns of symptom reporting during pregnancy comparing opioid maintained and control women",
abstract = "Objective: To characterize the range of symptoms experienced by pregnant methadone-maintained (MM) and buprenorphinemaintained (BM) women to determine whether these differ from those experienced by a control group of nonopioid exposed pregnant women. Opioid-maintained (OM) patients report high rates of symptoms related to direct opioid effects and withdrawal. Pregnancy is associated with a range of symptoms, some overlapping with opioid effects and withdrawal. Methods: Prospective, nonrandomized, open-label comparison study undertaken in a large teaching maternity hospital in South Australia. Pregnant BM(n=25),MM(n=25) and nonopioid exposed controls (n=25) were recruited and matched for age, parity, gravidity, alcohol consumption, and smoking status. Symptom report patterns, maternal withdrawal, and additional substance use were assessed. Results: MM women reported 10 and BM women reported 2 symptoms throughout pregnancy at rates greater than controls.Methadonemaintained women reported significantly (P < 0.05) more symptoms than BM women compared to controls throughout pregnancy. Methadone-maintained women reported 8 and BM women reported 3 symptoms in the third trimester at rates greater than controls. Methadone-maintained women reported greater opioid withdrawal than controls; this did not occur in BM women. Additional substance use was comparable between BM and MM women but greater than controls. Conclusions: Patterns of symptom reports may have clinical implications for maternal and fetal health during pregnancy for OM women including optimization of opioid dosing regimens, education regardingmaternal nutritional intake and preventing postnatal depression, thereby ensuring maternal health and fetal development during pregnancy and enhancing mother-infant bonding and healthy child development postnatally.",
keywords = "Buprenorphine, Methadone, Opioid maintained, Pregnancy, Symptom",
author = "Gordon, {Andrea L.} and Lopatko, {Olga V.} and Helen Stacey and Vicki Pearson and Anna Woods and Ann Fisk and White, {Jason M.}",
year = "2012",
month = "12",
doi = "10.1097/ADM.0b013e31826b299d",
language = "English (US)",
volume = "6",
pages = "258--264",
journal = "Journal of Addiction Medicine",
issn = "1932-0620",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Patterns of symptom reporting during pregnancy comparing opioid maintained and control women

AU - Gordon, Andrea L.

AU - Lopatko, Olga V.

AU - Stacey, Helen

AU - Pearson, Vicki

AU - Woods, Anna

AU - Fisk, Ann

AU - White, Jason M.

PY - 2012/12

Y1 - 2012/12

N2 - Objective: To characterize the range of symptoms experienced by pregnant methadone-maintained (MM) and buprenorphinemaintained (BM) women to determine whether these differ from those experienced by a control group of nonopioid exposed pregnant women. Opioid-maintained (OM) patients report high rates of symptoms related to direct opioid effects and withdrawal. Pregnancy is associated with a range of symptoms, some overlapping with opioid effects and withdrawal. Methods: Prospective, nonrandomized, open-label comparison study undertaken in a large teaching maternity hospital in South Australia. Pregnant BM(n=25),MM(n=25) and nonopioid exposed controls (n=25) were recruited and matched for age, parity, gravidity, alcohol consumption, and smoking status. Symptom report patterns, maternal withdrawal, and additional substance use were assessed. Results: MM women reported 10 and BM women reported 2 symptoms throughout pregnancy at rates greater than controls.Methadonemaintained women reported significantly (P < 0.05) more symptoms than BM women compared to controls throughout pregnancy. Methadone-maintained women reported 8 and BM women reported 3 symptoms in the third trimester at rates greater than controls. Methadone-maintained women reported greater opioid withdrawal than controls; this did not occur in BM women. Additional substance use was comparable between BM and MM women but greater than controls. Conclusions: Patterns of symptom reports may have clinical implications for maternal and fetal health during pregnancy for OM women including optimization of opioid dosing regimens, education regardingmaternal nutritional intake and preventing postnatal depression, thereby ensuring maternal health and fetal development during pregnancy and enhancing mother-infant bonding and healthy child development postnatally.

AB - Objective: To characterize the range of symptoms experienced by pregnant methadone-maintained (MM) and buprenorphinemaintained (BM) women to determine whether these differ from those experienced by a control group of nonopioid exposed pregnant women. Opioid-maintained (OM) patients report high rates of symptoms related to direct opioid effects and withdrawal. Pregnancy is associated with a range of symptoms, some overlapping with opioid effects and withdrawal. Methods: Prospective, nonrandomized, open-label comparison study undertaken in a large teaching maternity hospital in South Australia. Pregnant BM(n=25),MM(n=25) and nonopioid exposed controls (n=25) were recruited and matched for age, parity, gravidity, alcohol consumption, and smoking status. Symptom report patterns, maternal withdrawal, and additional substance use were assessed. Results: MM women reported 10 and BM women reported 2 symptoms throughout pregnancy at rates greater than controls.Methadonemaintained women reported significantly (P < 0.05) more symptoms than BM women compared to controls throughout pregnancy. Methadone-maintained women reported 8 and BM women reported 3 symptoms in the third trimester at rates greater than controls. Methadone-maintained women reported greater opioid withdrawal than controls; this did not occur in BM women. Additional substance use was comparable between BM and MM women but greater than controls. Conclusions: Patterns of symptom reports may have clinical implications for maternal and fetal health during pregnancy for OM women including optimization of opioid dosing regimens, education regardingmaternal nutritional intake and preventing postnatal depression, thereby ensuring maternal health and fetal development during pregnancy and enhancing mother-infant bonding and healthy child development postnatally.

KW - Buprenorphine

KW - Methadone

KW - Opioid maintained

KW - Pregnancy

KW - Symptom

UR - http://www.scopus.com/inward/record.url?scp=84871220921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871220921&partnerID=8YFLogxK

U2 - 10.1097/ADM.0b013e31826b299d

DO - 10.1097/ADM.0b013e31826b299d

M3 - Article

VL - 6

SP - 258

EP - 264

JO - Journal of Addiction Medicine

JF - Journal of Addiction Medicine

SN - 1932-0620

IS - 4

ER -